Safety and Efficacy Study of VIS649 for IgA Nephropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

155

Participants

Timeline

Start Date

July 20, 2020

Primary Completion Date

May 19, 2023

Study Completion Date

June 18, 2023

Conditions
Immunoglobulin A NephropathyGlomerular DiseaseIgAN
Interventions
DRUG

Dose-Placebo

Unit Dose Strength - 0.9%.

DRUG

Low Dose-VIS649

Dose Level = Low

DRUG

Medium Dose-VIS649

Dose Level = Medium

DRUG

High Dose-VIS649

Dose Level = High

Trial Locations (93)

800

Visterra Investigational Site, Colombo

1101

Visterra Investigational Site, Diliman

1102

Visterra Investigational Site, Quezon City

2065

Visterra Investigational Site, Saint Leonards

2305

Visterra Investigational Site, New Lambton Heights

3080

Visterra Investigational Site, Seoul

3722

Visterra Investigational Site, Seoul

4560

Visterra Investigational Site, Nambour

5355

Visterra Investigational Site, Gangdong

6009

Visterra Investigational Site, Nedlands

8025

Visterra Investigational Site, Barcelona

8907

Visterra Investigational Site, L'Hospitalet de Llobregat

10016

Visterra Investigational Site, New York

10310

Visterra Investigational Site, Bangkok

10400

Visterra Investigational Site, Ratchathewi

13620

Visterra Investigational Site, Seongnam-si

14004

Visterra Investigational Site, Córdoba

14068

Visterra Investigational Site, Anyang-si

18017

Visterra Investigational Site, Bethlehem

18450

Visterra Investigational Site, Hwaseong-si

20000

Visterra Investigational Site, Kandy

20104

Visterra Investigational Site, Keelung

23142

Visterra Investigational Site, New Taipei City

23561

Visterra Investigational Site, New Taipei City

25100

Visterra Investigational Site, Kuantan

27599

Visterra Investigational Site, Chapel Hill

28034

Visterra Investigational Site, Madrid

30046

Visterra Investigational Site, Lawrenceville

35294

Visterra Investigational Site, Birmingham

38801

Visterra Investigational Site, Tupelo

39010

Visterra Investigational Site, Santander

40705

Visterra Investigational Site, Xitun

41009

Visterra Investigational Site, Seville

41013

Visterra Investigational Site, Seville

41200

Visterra Investigational Site, Klang

43210

Visterra Investigational Site, Columbus

46017

Visterra Investigational Site, Valencia

50200

Visterra Investigational Site, Chiang Mai

56000

Visterra Investigational Site, Kuala Lumpur

59100

Visterra Investigational Site, Kuala Lumpur

70300

Visterra Investigational Site, Seremban

70808

Visterra Investigational Site, Baton Rouge

80230

Visterra Investigational Site, Denver

82445

Visterra Investigational Site, Kaohsiung City

83301

Visterra Investigational Site, Kaohsiung City

93036

Visterra Investigational Site, Oxnard

94305

Visterra Investigational Site, Palo Alto

110060

Visterra Investigational Site, New Delhi

160012

Visterra Investigational Site, Chandigarh

169608

Visterra Investigational Site, Singapore

226014

Visterra Investigational Site, Raebareli

308433

Visterra Investigational Site, Singapore

500012

Visterra Investigational Site, Hyderabad

500082

Visterra Investigational Site, Hyderabad

560034

Visterra Investigational Site, Bengaluru

560054

Visterra Investigational Site, Bangalore

576104

Visterra Investigational Site, Manipal

632004

Visterra Investigational Site, Vellore

673008

Visterra Investigational Site, Kozhikode

695011

Visterra Investigational Site, Thiruvananthapuram

999077

Visterra Investigational Site, Kowloon

90027-5969

Visterra Investigational Site, Los Angeles

94305-2200

Visterra Investigational Site, Stanford

70121-2429

Visterra Investigational Site, New Orleans

21201-1544

Visterra Investigational Site, Baltimore

77030-4202

Visterra Investigational Site, Houston

77054-2854

Visterra Investigational Site, Houston

T2N 2T9

Visterra Investigational Site, Calgary

L6R 3J7

Visterra Investigational Site, Brampton

H4A 3J1

Visterra Investigational Site, Montreal

Unknown

Visterra Investigational Site, Hong Kong

Visterra Investigational Site, Hong Kong

Visterra Investigational Site, Tsuen Wan

Visterra Investigational Site, Nugegoda

470-1192

Visterra Investigational Site, Toyoake-shi

Visterra Investigational Site, Minatoku

177-8521

Visterra Investigational Site, Tokyo

326-0843

Visterra Investigational Site, Ashikaga

Visterra Investigational Site, Ashikaga-Shi

113-8431

Visterra Investigational Site, Bunkyō City

634-8522

Visterra Investigational Site, Kashihara-shi

951-8520

Visterra Investigational Site, Niigata

162-8666

Visterra Investigational Site, Shinjuku-Ku

305-876

Visterra Investigational Site, Tsukuba

279-0021

Visterra Investigational Site, Urayasu-Shi

130-872

Visterra Investigational Site, Seoul

431-070

Visterra Investigational Site, Anyang

05030

Visterra Investigational Site, Seoul

BD5 0NA

Visterra Investigational Site, Bradford

E11BB

Visterra Investigational Site, London

SE5 9RS

Visterra Investigational Site, London

W12 0HS

Visterra Investigational Site, London

M6 8HD

Visterra Investigational Site, Salford

All Listed Sponsors
lead

Visterra, Inc.

INDUSTRY

NCT04287985 - Safety and Efficacy Study of VIS649 for IgA Nephropathy | Biotech Hunter | Biotech Hunter